Purpose: To evaluate the outcome of Stereotactic Body Radiation Therapy (SBRT) with Volumetric Modulated Arc Therapy (VMAT) for thoracic node metastases.
Results: 18 out of 29 patients presented with isolated thoracic node metastases with no other sites of disease. Median prescribed dose was 45Gy (range 30-60Gy).Acute toxicity was recorded as G0 in 28 patients, while one patient was scored as G1. Late toxicity was G0 in 26 patients, one patient was scored G1, one as G2, and one as G4 presented acute myocardial infarction.During follow up, the best local response was complete remission in 14 patients and partial remission in 11 patients. With a median follow up of 12 months (range 2-35) 9 patients died from disease progression, 10 were still alive with distant metastases, 5 had a locally controlled disease and 5 patients were disease free.The median OS estimated was 18 months (76%, 49% at one, two years). The median PFS was 9 months (28%, 17% at one, two years).
Materials And Methods: Twenty-nine patients with 32 thoracic nodes metastases were treated with SBRT in our institution. Toxicities and response were assessed. Overall Survival (OS) and Progression Free Survival (PFS) were evaluated.
Conclusions: SBRT is an efficient treatment for thoracic node metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288189 | PMC |
| http://dx.doi.org/10.18632/oncotarget.10826 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Necessity of Lymphadenectomy for Non-Small Cell Lung Cancer Smaller Than 6 mm in Solid Size.
Ann Surg Oncol
January 2025
Department of Thoracic Surgery, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: This study aimed to evaluate the necessity of lymph node sampling for specific non-small cell lung cancer (NSCLC).
Methods: Patients with small-size (≤2 cm) NSCLC who underwent surgical resection between 2009 and 2022 were retrospectively screened. The characteristics of patients with nodal metastasis were demonstrated.
LcProt: Proteomics-based identification of plasma biomarkers for lung cancer multievent, a multicentre study.
Clin Transl Med
January 2025
Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China.
Background: Plasma protein has gained prominence in the non-invasive predicting of lung cancer. We utilised Zeolite Zotero NaY-based plasma proteomics to investigate its potential for multiple event predicting, including lung cancer diagnosis (task #1), lymph node metastasis detection (task #2) and tumour‒node‒metastasis (TNM) staging (task #3).
Methods: A total of 4703 plasma proteins were quantified from 241 participants based on a prospective cohort of 2757 participants.
Current immunotherapy for thymic epithelial tumors: a narrative review.
Mediastinum
October 2024
Department of General Thoracic Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Background And Objective: Thymic epithelial tumors (TETs) are the most common neoplasm of the prevascular mediastinal compartment and are characterized by their rarity and variable clinical presentation. The present study aimed to explore the current management of patients with TET with a special focus on immunotherapy for advanced disease.
Methods: Relevant studies published between 1981 and 2024 were searched in PubMed using search terms "Thymoma", "Thymic cancer", "Myasthenia gravis", "Radiation therapy", "Surgery", and "Immunotherapy".
Pulmonary tuberculosis presenting as a hilar mass.
BMJ Case Rep
January 2025
Pulmonary Medicine, Siksha O Anusandhan University Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Orissa, India.
Tuberculosis (TB) is a great mimicker due to its various unusual and atypical presentations. Mass-like lesions in thoracic radiology may raise the suspicion of lung malignancy. A man in his early 50s complained of cough, low-grade fever and dyspnoea.
View Article and Find Full Text PDFBilateral Mediastinal Lymphadenectomy Is Associated With Potential Survival Advantages in Patients With Stage I Non-Small Cell Lung Cancer Who Undergo Lung Resection.
JCO Glob Oncol
January 2025
Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Purpose: The optimal lymphadenectomy approach for solid-dominant stage I non-small cell lung cancer (NSCLC) is controversial. We compared postlobectomy survival outcomes to elucidate.
Materials And Methods: Patients diagnosed with solid-dominant stage I NSCLC between 2008 and 2015 were included and grouped according to the mode of lymphadenectomy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!